DDInter1826 DDInter1678
A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in many types of human cancer. Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants. In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids. In May 2015, the FDA approved sirolimus for the treatment of patients with lymphangioleiomyomatosis. In November 2021, albumin-bound sirolimus for intravenous injection was approved by the FDA for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumour (PEComa). Sirolimus was also investigated in other cancers such as skin cancer, Kaposi’s Sarcoma, cutaneous T-cell lymphomas, and tuberous sclerosis. The topical formulation of sirolimus, marketed as HYFTOR, was approved by the FDA in April 2022: this marks the first topical treatment approved in the US for facial angiofibroma associated with tuberous sclerosis complex.
Tolazamide {u} (Compound) upregulates {v} (Gene) TSC22D3
TSC22D3 {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Tolazamide {u} (Compound) downregulates {v} (Gene) ADGRG1
ADGRG1 {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Tolazamide {u} (Compound) downregulates {v} (Gene) IER3
IER3 {u} (Gene) is downregulated by {v} (Compound) Sirolimus
Tolazamide {u} (Compound) causes {v} (Side Effect) Dizziness
Dizziness {u} (Side Effect) is caused by {v} (Compound) Sirolimus
Tolazamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Tolazamide {u} (Compound) upregulates {v} (Gene) TSC22D3
TSC22D3 {u} (Gene) is upregulated by {v} (Compound) Tacrolimus
Tacrolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Tolazamide {u} (Compound) downregulates {v} (Gene) ADGRG1
ADGRG1 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Tolazamide {u} (Compound) downregulates {v} (Gene) IER3
IER3 {u} (Gene) regulates {v} (Gene) P4HA2
P4HA2 {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Tolazamide {u} (Compound) causes {v} (Side Effect) Dizziness
Dizziness {u} (Side Effect) is caused by {v} (Compound) Tacrolimus
Tacrolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Tolazamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} (Compound) upregulates {v} (Gene) CNPY3
CNPY3 {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Tolazamide (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Sirolimus (Compound)
Tolazamide (Compound) downregulates ADGRG1 (Gene) and ADGRG1 (Gene) is upregulated by Sirolimus (Compound)
Tolazamide (Compound) downregulates IER3 (Gene) and IER3 (Gene) is downregulated by Sirolimus (Compound)
Tolazamide (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Sirolimus (Compound)
Tolazamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Tolazamide (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Tacrolimus (Compound) and Tacrolimus (Compound) resembles Sirolimus (Compound)
Tolazamide (Compound) downregulates ADGRG1 (Gene) and ADGRG1 (Gene) is upregulated by Temsirolimus (Compound) and Temsirolimus (Compound) resembles Sirolimus (Compound)
Tolazamide (Compound) downregulates IER3 (Gene) and IER3 (Gene) regulates P4HA2 (Gene) and P4HA2 (Gene) is upregulated by Sirolimus (Compound)
Tolazamide (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Tacrolimus (Compound) and Tacrolimus (Compound) resembles Sirolimus (Compound)
Tolazamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide (Compound) upregulates CNPY3 (Gene) and CNPY3 (Gene) is upregulated by Sirolimus (Compound)